Clinical Trial Search

Primary: Seroprotection, Non-Atopic Dermatitis (AD), Intradermal vs. Moderate to Severe Atopic Dermatitis, Intradermal - Influenza B — 34.4; 22.5 percentage of participants…

Primary: Achievement of 75% Reduction From Baseline in the Eczema Area and Severity Index (EASI 75 Response) at Week 12 (Day 84) — 32.3; 37.4 Percentage (%)

Primary: Number of Allergen-induced Eosinophils in the Skin — 11.95; 71.15 cells/mm2

Primary: Fold-Change in Epidermal Thickness of Lesional Skin — 1.15; 1.5; 1.18; -1 fold-change

Primary: Percentage of Participants With Hand and Foot Investigator Global Assessment (IGA) 0 or 1 at Week 16 — 16.7; 40.3 Percentage of participants — p==0.0030

Primary: Percentage of Participants Who Have an Investigator Global Assessment (IGA) Score of Clear or Almost Clear (0 or 1) at Week 12 and a Minimum 2 Grade Improvement in IGA…

Primary: Insulin Sensitivity Difference Between Patients With Atopic Dermatitis and Controls — 9.8; 9.2 mg glucose/kg body mass/minute

Primary: Part 1 (Phase I) Primary: Maximum Tolerable Dose — 29.2 Grams of IP per application

Primary: Change in Percentage of Body Involvement — -2.0; 0.15 Change of percentage in body involvement

Primary: Percent Change of Trans Epidermal Water Loss (TEWL) With Use of Eucerin Lotion — 21.4 percent change

Primary: Bacteriological Culture — 13; 3; 16; 5 participants

Primary: Percent Change in Eczema Area and Severity Index (EASI) Score — -61.15; -57.05; -64.27; -51.42 percent of change — p=0.0090

Primary: Percentage of Participants With ≥75% Reduction From Baseline in Eczema Area and Severity Index (EASI) Score (EASI-75) — 76.0 percentage of participants

Primary: Heterozygous for Filaggrin (FLG) Null Mutations — 1; 4 participants

Primary: Changes in SCORAD Index — -3.0; -5.7 units on a scale